Main Article Content

Joel Lexchin http://orcid.org/0000-0001-5120-8029


Ontario Drug Benefit Formulary


Invited Editorial

Abstract 90 | pdf Downloads 54


1. Rawson N, Chhabra A. Public reimbursement of prescription drugs used for off-label indications in Ontario. J Pop Ther Clin Pharmacol 2018;25(2).
2. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database System Rev 2014;9: CD011230.

3. Eguale T, Buckeridge D, Verma A, et al. Association of off-label dur use and adverse drug events in an adult population. JAMA Int Med 2016;176:55–63.
4. CADTH. Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions - recommendations report. Ottawa; 2016. Available at: https://www.cadth.ca/anti-vascular-endothelial-growth-factor-drugs-retinal-conditions
5. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Data Syst Rev 2017;2: MR000033.